Analysts’ updated eps estimates for Thursday, October 17th:

Abbott Laboratories (NYSE:ABT) had its underperform rating reiterated by analysts at William Blair.

Core Laboratories (NYSE:CLB) was downgraded by analysts at ABN Amro from a buy rating to a hold rating.

New Oriental Education & Tech Grp (NYSE:EDU) was upgraded by analysts at JPMorgan Chase & Co. from a neutral rating to an overweight rating. JPMorgan Chase & Co. currently has $143.00 target price on the stock, up from their previous target price of $88.00.

First Quantum Minerals (OTCMKTS:FQVLF) was upgraded by analysts at Deutsche Bank AG from a hold rating to a buy rating.

Global Payments (NYSE:GPN) had its outperform rating reiterated by analysts at William Blair.

Johnson & Johnson (NYSE:JNJ) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. Zacks Investment Research currently has $142.00 target price on the stock. According to Zacks, “J&J beat earnings and sales estimates in Q3 and raised the guidance for 2019. J&J is witnessing significant generic/biosimilar headwinds in the Pharma unit in 2019. However, J&J’s Pharma unit is performing above-market levels supported by contribution from new drugs like Tremfya and successful label expansion of cancer drugs like Imbruvica and Darzalex and immunology drug, Stelara. J&J is also making rapid progress with its pipeline and line extensions. It has already gained FDA approval for two new drugs in 2019, Balversa and Spravato. J&J’s shares have outperformed the industry this year. Headwinds like biosimilar/generic competition and pricing pressure remain. J&J faces numerous lawsuits, which allege personal injuries to patients caused by the use of its products. These are also an overhang on the stock.”

Oppenheimer Holdings Inc. initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX). The firm issued an outperform rating and a $2.00 price target on the stock.

Netflix (NASDAQ:NFLX) was downgraded by analysts at Huber Research from an overweight rating to an underweight rating.

Penumbra (NYSE:PEN) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $165.00 price target on the stock. According to Zacks, “Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company’s portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California. “

Phreesia (NYSE:PHR) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Phreesia Inc. provides a patient intake management platform. The company’s SaaS platform engages patients in their care and provides a modern, consistent experience, while enabling healthcare organizations to optimize their staffing, boost profitability and enhance clinical care. Phreesia Inc. is based in New York. “

PLx Pharma (NASDAQ:PLXP) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “PLx Pharma Inc. is a specialty pharmaceutical company. It focused on developing clinically validated and patent-protected PLxGuard(TM) delivery system to provide safe and effective aspirin products. PLx Pharma Inc., formerly known as Dipexium Pharmaceuticals Inc., is based in NEW YORK, United States. “

Pinnacle Financial Partners (NASDAQ:PNFP) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Pinnacle Financial Partners, Inc. Provides a full range of banking, investment, trust, mortgage and insurance products and services designed for businesses and their owners and individuals interested in a comprehensive relationship with their financial institution. “

Primo Water (NASDAQ:PRMW) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Prime Water Corporation operates as a provider of three- and five-gallon purified bottled water and water dispensers sold through major retailers nationwide. The Company’s water bottles can be sanitized and reused, crushed and recycled. Also, it provides water bottle exchange solution for its retail customers. It operates through two segments, Primo Bottled Water Exchange and Primo Products. Prime Water Corporation is headquartered in Winston-Salem, North Carolina. “

Perspecta (NASDAQ:PRSP) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Perspecta delivers IT services and business solutions to all levels of government in the United States. Their enterprise-based offerings and solutions for U.S. government customers include: Cloud, Platform and IT Outsourcing Services, Enterprise and Cloud Applications, Enterprise Security, Mobility and Workplace, and Analytics. They have existing contracts with a range of public sector entities ranging from the U.S. Department of Veteran Affairs and the U.S. Department of Defense, to the United States Postal Service, the U.S. National Aeronautics and Space Administration, the U.S. Food and Drug Administration and large state and local government customers such as the county of San Diego, California. “

Prevail Therapeutics (NASDAQ:PRVL) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $11.00 price target on the stock. According to Zacks, “Prevail Therapeutics Inc. is a gene therapy company. It focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company’s product candidate consists of PR001, PR006 and PR004 which are in clinical stage. Prevail Therapeutics Inc. is based in New York. “

Pluristem Therapeutics (NASDAQ:PSTI) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $4.25 price target on the stock. According to Zacks, “PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. “

P.A.M. Transportation Services (NASDAQ:PTSI) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “P.A.M. Transportation Services, Inc. is an irregular route, common and contract motor carrier authorized to transport general commodities. The freight consists primarily of automotive parts, consumer goods, such as general retail store merchandise, and products from the manufacturing sector, such as heating and air conditioning units. All freight is transported as truckload quantities. “

Qiagen (NYSE:QGEN) was upgraded by analysts at Wolfe Research from a peer perform rating to an outperform rating.

TAL Education Group (NYSE:TAL) had its overweight rating reaffirmed by analysts at JPMorgan Chase & Co..

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.